Arcalyst Q3 revenue up 58% to $286M, 2026 sales outlook raised

Kiniksa reported third quarter revenue of $286 million driven by sales of ARCALYST, an IL-1 modulator for recurrent pericarditis, significantly up from the prior year. The company raised its full-year sales guidance to $1.045-$1.05 billion.